Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
Inventors:
Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
Abstract: Provided herein are combination vaccines comprising antigens for protecting a subject against at least diphtheria, tetanus, pertussis and Hib, wherein: (a) the antigen for protecting against Hib is a conjugate of a Hib capsular saccharide; (b) the concentration of the Hib conjugate in the vaccine is <15 ?g/ml; and (c) the Hib conjugate has never been lyophilized.
Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 3, or 4, the nucleotide sequence set forth in SEQ ID NO:1, 9, 10, or 11, as well as variants and fragments thereof.
Type:
Grant
Filed:
October 18, 2013
Date of Patent:
February 16, 2016
Assignee:
Athenix Corp.
Inventors:
Nalini Manoj Desai, Jill Hinson, Deepa Balasubramanian, Kimberly S. Sampson, Daniel J. Tomso, Duane Alan Lehtinen, Nicholas B. Duck, Rong Guo, Volker Heinrichs
Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
Abstract: The present invention relates to method of detecting activity of a sample. Some methods involve detecting a neo-binding-site created by the activity such as detecting an activity of a protease by detecting a neo-binding-site created by cleavage of a substrate by the protease.
Abstract: Disclosed are substantially purified Plasmodium sporozoites and preparations of Plasmodium sporozoites substantially separated from attendant non-sporozoite material, where the preparations of Plasmodium sporozoites have increasing levels of purity. Vaccines and pharmaceutical compositions comprising purified Plasmodium sporozoites are likewise provided. Methods of purifying preparations of Plasmodium sporozoites are also provided.
Type:
Grant
Filed:
March 27, 2015
Date of Patent:
January 26, 2016
Assignee:
SANARIA INC.
Inventors:
B. Kim Lee Sim, Minglin Li, Richard E. Stafford, Stephen L. Hoffman
Abstract: Described herein are methods and systems for O-glycosylating proteins in vivo or in vitro in any prokaryotic organism. In these methods and systems, DNA comprising a gene that produces a PglL-like oligosaccharyltransferase and DNA comprising a gene that produces a protein to be O-glycosylated are used. The PglL-like oligosaccharyltransferase facilitates the covalent attachment of the glycan to the protein to produce the O-glycosylated protein. The methods and systems described herein provide an approach for the design and production of new vaccines and therapeutic agents for the treatment of various diseases.
Type:
Grant
Filed:
December 13, 2007
Date of Patent:
January 19, 2016
Assignee:
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
Abstract: The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides.
Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.
Type:
Grant
Filed:
February 11, 2011
Date of Patent:
December 29, 2015
Assignee:
The Governors of the University of Alberta
Abstract: An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor.
Type:
Grant
Filed:
July 13, 2015
Date of Patent:
December 22, 2015
Assignee:
Case Western Reserve University
Inventors:
Clifford Harding, W. Henry Boom, Michael G. Drage, Nicole D. Pecora
Abstract: The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method.
Type:
Grant
Filed:
August 13, 2014
Date of Patent:
December 15, 2015
Assignee:
MERZ PHARMA GmbH & CO. KGaA
Inventors:
Harold Victor Taylor, Karl-Heinz Eisele, Cornelia Brunn
Abstract: Provided herein are prime-boost regimens and materials used therein. The prime-boost regimens enhance the immune response to a target antigen. The vaccines used for boost are comprised of recombinant attenuated metabolically active Listeria that encodes an expressible antigen that is cross-reactive with the target antigen. In some examples, the immune response is a cellular immune response.
Type:
Grant
Filed:
January 5, 2015
Date of Patent:
December 1, 2015
Assignee:
Aduro Biotech, Inc.
Inventors:
Thomas W. Dubensky, Jr., Dirk G. Brockstedt, Meredith Lai Ling Leong, Keith S. Bahjat
Abstract: The present invention provides methods and compositions to reduce prevalence of plasmids in microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such compositions. Means are provided to reduce the copy numbers of antibiotic resistance genes, and to confer phage binding to cells lacking receptors for those phage.
Type:
Grant
Filed:
March 10, 2009
Date of Patent:
November 24, 2015
Assignee:
Gangagen, Inc.
Inventors:
C. B. Appaiah, Jayashella Manur, Bharathi Sriram
Abstract: The present invention provides methods of detecting Borrelia species in a sample (e.g., a sample from a patient suspected of being infected). In particular, the present invention provides compositions and methods for detecting the presence of Borrelia proteins, nucleic acid sequences encoding these proteins, and subject antibodies to these proteins, where the proteins are selected from those listed in Table 3, including: BB0279 (FLiL), BBK19, BBK07, BB0286 (FlbB), BBG33, BBL27, BBN34, BBP34, BBQ42, BBQ34, BBM34, BBN27, and BBH13.
Type:
Grant
Filed:
September 20, 2012
Date of Patent:
November 10, 2015
Assignee:
The Regents of the University of California
Abstract: The invention provides novel immunogenic proteins LigA and LigB from Leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.
Type:
Grant
Filed:
November 6, 2014
Date of Patent:
November 3, 2015
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Yung-Fu Chang, Raghavan U. M Palaniappan
Abstract: Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity.
Type:
Grant
Filed:
July 26, 2014
Date of Patent:
October 27, 2015
Assignee:
The Regents of the University of California
Inventors:
Valerie A. Kickhoefer, Leonard H. Rome, Kathleen A. Kelly, Cheryl I. Champion
Abstract: High affinity antibodies for binding epitopes of BoNT/B and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/B in a sample.
Type:
Grant
Filed:
October 20, 2014
Date of Patent:
September 29, 2015
Assignee:
The United States of America, as represented by The Secretary of Agriculture
Inventors:
Larry H. Stanker, Miles C. Scotcher, Luisa W. Cheng, Robert M. Hnasko, Jeffery A. McGarvey
Abstract: The invention relates to three isolated DNA molecules that encode for proteins, BigL1, BigL2 and BigL3, in the Leptospira sp bacterium which have repetitive Bacterial-Ig-like (Big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for BigL1, BigL2 and BigL3 proteins are used for the diagnosis and prevention of infection with Leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance.
Type:
Grant
Filed:
May 19, 2014
Date of Patent:
September 15, 2015
Assignees:
Cornell Research Foundation, Inc., The Regents of the University of California, The United States of America represented by the Department of Veterans Affairs, Fundação Oswaldo Cruz—FIOCRUZ
Inventors:
Albert I. Ko, Mitermayer Galvão Reis, Julio Henrique Rosa Croda, Isadora Cristina Siqueira, David A. Haake, James Matsunaga, Lee W. Riley, Michele Barocchi, Tracy Ann Young
Abstract: The invention concerns the detection of pathogenic mycobacterium comprising Mycobacterium avium subsp. paratuberculosis (Map) and genomic variants in a bulk milk sample, and more particularly a method for herd management that stratifies the risk of bulk tank milk lots derived from diagnostic-tested subgroups potentially containing DNA from pathogenic mycobacterium including Map. The method involves creating defined risk groups (categories) of milk-producing animals, such as dairy cows, for the presence of Map or related genomic variants in their milk. Another aspect of the invention concerns a method to strengthen the ability of milk-producing animals to resist environmental challenges by Map based on identifying those animals that have and maintain a low antibody level to Map using their female progeny as replacement animals.
Abstract: A modified protein of the single strand DNA-binding domain, SSB family comprising a detectable label is disclosed. The label has detectable characteristics which alter on binding single stranded DNA. The protein is thus useful in an assay for single stranded DNA.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
September 1, 2015
Assignees:
MEDICAL RESEARCH COUNCIL, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Mark Dillingham, Stephen C. Kowalczykowski, Martin Webb